Structural MR and amyloid PET imaging have been proposed by the National Institute on Aging as methods to subdivide preclinical Alzheimer Disease (AD) into discrete stages of (1) amyloidosis, followed by (2) amyloidosis plus neurodegeneration, both of which precede (3) subtle cognitive decline, followed by the clinical progression to mild cognitive impairment (MCI) and AD dementia. The HASD Imaging Core will provide MR and PET support to the HASD Projects to test how these proposed stages relate to the transition for normal to impaired cognitive performance (Project 1), sleep disturbance (Project 2), and genetic analyses (Project 3). The following Specific Aims will be pursued: I. Combined PET-MR scanning for brain structure, function, and amyloid pathology. For the entire combined HASD and ADRC cohorts, we will perform brain MRI and florbetapir F18 (AV45) amyloid imaging every three years (200 participants/year). II. Provide data processing for these imaging tests, to include (2a) matched regional volumes, thicknesses, and quantitative PET analyses, (2b) quantitative individual longitudinal participant reports compared normative values generated by the cohort, and (2c) grouped regional reports based on classifications derived from the Projects and Cores. III. Generate an online accessible resource containing source imaging (DICOM), processed imaging, and clinical and biomarker characterization to facilitate data sharing outside of our institution, including contributions to the private-public partnership developed by JC Morris, HASD PI, and T. Benzinger, HASD Imaging Core Leader, with Avid/Lilly. This partnership allows funding for longitudinal MR and amyloid PET imaging for the entire cohort.
Core E: Imaging Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.
|Su, Yi; Blazey, Tyler M; Snyder, Abraham Z et al. (2015) Partial volume correction in quantitative amyloid imaging. Neuroimage 107:55-64|
|Shim, Yong Soo; Yang, Dong-Won; Roe, Catherine M et al. (2015) Pathological correlates of white matter hyperintensities on magnetic resonance imaging. Dement Geriatr Cogn Disord 39:92-104|
|Wang, Li-San; Naj, Adam C; Graham, Robert R et al. (2015) Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol 72:209-16|
|Ghoshal, Nupur; Perry, Arie; McKeel, Daniel et al. (2015) Variably Protease-sensitive Prionopathy in an Apparent Cognitively Normal 93-Year-Old. Alzheimer Dis Assoc Disord 29:173-6|
|Hurth, Kyle; Tarawneh, Rawan; Ghoshal, Nupur et al. (2015) Whipple's disease masquerades as dementia with Lewy bodies. Alzheimer Dis Assoc Disord 29:85-9|
|Aschenbrenner, Andrew J; Balota, David A; Tse, Chi-Shing et al. (2015) Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. Neuropsychology 29:368-81|
|Lim, Miranda M; Gerstner, Jason R; Holtzman, David M (2014) The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag 4:351-62|
|Pizzie, Rachel; Hindman, Halley; Roe, Catherine M et al. (2014) Physical activity and cognitive trajectories in cognitively normal adults: the adult children study. Alzheimer Dis Assoc Disord 28:50-7|
|Fagan, Anne M; Xiong, Chengjie; Jasielec, Mateusz S et al. (2014) Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 6:226ra30|
|Harari, Oscar; Cruchaga, Carlos; Kauwe, John S K et al. (2014) Phosphorylated tau-A?42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry 75:723-31|
Showing the most recent 10 out of 529 publications